Y Intercept Hong Kong Ltd purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 134,566 shares of the biotechnology company’s stock, valued at approximately $23,682,000. Biogen comprises 0.5% of Y Intercept Hong Kong Ltd’s investment portfolio, making the stock its 11th biggest position. Y Intercept Hong Kong Ltd owned approximately 0.09% of Biogen as of its most recent SEC filing.
Several other large investors have also modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Biogen by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock worth $3,070,514,000 after buying an additional 157,857 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Biogen by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock worth $736,435,000 after buying an additional 130,618 shares during the period. Norges Bank bought a new stake in shares of Biogen during the 4th quarter worth $464,408,000. Invesco Ltd. boosted its holdings in shares of Biogen by 4.2% during the 3rd quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock worth $338,731,000 after buying an additional 98,001 shares during the period. Finally, AQR Capital Management LLC boosted its holdings in Biogen by 30.7% in the 3rd quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock valued at $248,809,000 after purchasing an additional 418,776 shares during the period. 87.93% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on BIIB. HC Wainwright reissued a “buy” rating on shares of Biogen in a report on Thursday, May 14th. UBS Group raised shares of Biogen from a “neutral” rating to a “buy” rating and increased their price target for the company from $185.00 to $225.00 in a report on Wednesday, April 22nd. Truist Financial reduced their price target on shares of Biogen from $193.00 to $189.00 and set a “hold” rating for the company in a report on Monday, April 13th. Evercore began coverage on shares of Biogen in a report on Friday, May 15th. They issued an “outperform” rating for the company. Finally, Rothschild & Co Redburn increased their price target on shares of Biogen from $180.00 to $190.00 in a report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $217.26.
Biogen Price Performance
NASDAQ:BIIB opened at $200.05 on Friday. The company has a 50-day moving average of $188.73 and a 200-day moving average of $184.31. The company has a market capitalization of $29.54 billion, a price-to-earnings ratio of 21.46 and a beta of 0.20. Biogen Inc. has a 52 week low of $121.05 and a 52 week high of $205.97. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06.
Biogen (NASDAQ:BIIB – Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period last year, the firm earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities research analysts anticipate that Biogen Inc. will post 14.18 earnings per share for the current fiscal year.
Biogen Company Profile
Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.
The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.
See Also
- Five stocks we like better than Biogen
- MarketBeat Week in Review – 06/08 – 06/12
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
